1-7 of 7
Wei Guo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors

Melissa L. Johnson, Beni B. Wolf, Judy S. Wang, Alexander Philipovskiy, Geoffrey I. Shapiro, Bruno Bockorny, Wei Guo, Jinshan Shen, Kai Yu Jen, MaryBeth LeRose, Tamieka Lauz Hunter, Mahesh Padval, Oleg Schmidt-Kittler, Namrata Bhatia, Sarita Dubey, Julia Suchomel, Johanna C. Bendell, Shekeab Jauhari, Jennifer Eng-Wong, Jessica J. Lin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF8.
https://doi.org/10.1158/1535-7163.MCT-24-0466
Published: 31 December 2024
View article titled, First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Open the PDF for First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract P02-02: First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors

Lipika Goyal, Mitesh Borad, Vivek Subbiah, Amit Mahipal, Suneel Kamath, Kabir Mody, Robin Katie Kelley, Richard Kim, Vaibhav Sahai, Anthony El-Khoueiry, Efrat Dotan, Oleg Schmidt-Kittler, Jinshan Shen, Kai Yu Jen, Alicia Deary, Wei Guo, Mahesh Padval, Cori Ann J. Sherwin, Charles Ferte, Beni Wolf, Alison M. Schram
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P02-02.
https://doi.org/10.1158/1535-7163.TARG-21-P02-02
Published: 01 December 2021
View article titled, Abstract P02-02: First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors
Journal Articles

Abstract A1: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors

Jian-Ming Xu, Lin Sheng, Yan Wang, Yu-Ling Chen, Ru Jia, Jian Wang, Ke Li, Yang Sai, Jing Li, Chuan Qi, Ye Hua, Wei-Guo Su
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A1.
https://doi.org/10.1158/1535-7163.TARG-15-A1
Published: 01 December 2015
View article titled, Abstract A1: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors
Journal Articles

Abstract B12: Co-inhibition of PI3K and Myc pathways is synthetic lethal to PTEN null T-ALL leukemia-initiating cells

Suzanne Schubbert, Anjelica Cardenas, Christopher Wei, Lingda Ma, Consuelo Garcia, Wei Guo, Hong Wu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): B12.
https://doi.org/10.1158/1535-7163.PMS-B12
Published: 01 May 2014
View article titled, Abstract B12: Co-inhibition of PI3K and Myc pathways is synthetic lethal to PTEN null T-ALL leukemia-initiating cells
Journal Articles

Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1)

Wei Guo, Shuhong Wu, Li Wang, Rui-yu Wang, Xiaoli Wei, Jinsong Liu, Bingliang Fang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (2): 441–448.
https://doi.org/10.1158/1535-7163.MCT-08-0839
Published: 11 February 2009
View article titled, Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1<em>H</em>-indole-3-carboxaldehyde (oncrasin-1)
Open the PDF for Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1<em>H</em>-indole-3-carboxaldehyde (oncrasin-1) in another window
Includes: Supplementary data
Journal Articles

Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines

Lourdes Toral-Barza, Wei-Guo Zhang, Xinyi Huang, Leonard A. McDonald, Edward J. Salaski, Laurel R. Barbieri, Wei-Dong Ding, Girija Krishnamurthy, Yong Bo Hu, Judy Lucas, Valerie S. Bernan, Ping Cai, Jeremy I. Levin, Tarek S. Mansour, James J. Gibbons, Robert T. Abraham, Ker Yu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11): 3028–3038.
https://doi.org/10.1158/1535-7163.MCT-07-0211
Published: 19 November 2007
View article titled, Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines
Open the PDF for Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines in another window
Journal Articles

Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells

Hongbo Zhu, Wei Guo, Lidong Zhang, John J. Davis, Fuminori Teraishi, Shuhong Wu, Xiaobo Cao, Jonathan Daniel, W. Roy Smythe, Bingliang Fang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (3): 451–456.
https://doi.org/10.1158/1535-7163.MCT-04-0162
Published: 14 March 2005
View article titled, Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells
Open the PDF for Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells in another window